# Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound

> **NCT07716228** · PHASE3 · RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 74 (estimated)

## Conditions studied

- Nausea and Vomiting Caused by Chemotherapy

## Interventions

- **DRUG:** Auricular point stimulation plus dexamethasone
- **DRUG:** Standard pharmacologic antiemetic regimen

## Key facts

- **NCT ID:** NCT07716228
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2026-12-06
- **Final completion:** 2026-12-12
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716228, "Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*